-
公开(公告)号：US11591392B2
公开(公告)日：2023-02-28
申请号：US16697653
申请日：2019-11-27
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号：US11306150B2
公开(公告)日：2022-04-19
申请号：US16476814
申请日：2018-01-10
Inventor： Robert J. Johnston , Andrew Rankin , Arathi Krishnakumar , Paul O. Sheppard , Arvind Rajpal
Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号：US10533052B2
公开(公告)日：2020-01-14
申请号：US16017489
申请日：2018-06-25
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
-
公开(公告)号：US20190330364A1
公开(公告)日：2019-10-31
申请号：US16476814
申请日：2018-01-10
Inventor： Robert J. Johnston , Andrew Rankin , Arathi Krishnakumar , Paul O. Sheppard , Arvind Rajpal
IPC: C07K16/28
Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号：US10358490B2
公开(公告)日：2019-07-23
申请号：US15694374
申请日：2017-09-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: A61K39/395 , C07K16/24 , C07K16/46 , A61K39/00
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
-
Patent Agency Ranking
公开(公告)号：US20160176963A1
公开(公告)日：2016-06-23
申请号：US14977789
申请日：2015-12-22
Applicant: Bristol-Myers Squibb Company
Inventor： Mark F. Maurer , Tseng-hui Timothy Chen , Brigitte Devaux , Mohan Srinivasan , Susan H. Julien , Paul O. Sheppard , Daniel F. Ardourel , Indrani Chakraborty
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/76 , C07K2317/92 , Y02A50/466
Abstract: The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.
Abstract translation: 本发明提供了结合人TIGIT（具有Ig和ITIM结构域的T细胞免疫受体）的抗体或其抗原结合片段，以及这些抗体或片段在治疗应用中的用途，例如用于治疗癌症或慢性 病毒感染。 这种治疗方法包括与其它免疫调节受体相互作用的抑制剂如PD-1 / PD-L1相互作用的联合治疗。 本发明还提供了编码抗体的重链和/或轻链可变区的多核苷酸，包含编码抗体的重链和/或轻链可变区的多核苷酸的表达载体，包含载体的细胞，以及制备抗体或 片段通过从细胞表达。
-
公开(公告)号：US08945553B2
公开(公告)日：2015-02-03
申请号：US13898544
申请日：2013-05-21
Applicant: Bristol-Myers Squibb Company
Inventor： Brenda L. Stevens , Alison Witte , Mark W. Rixon , Josephine M. Cardarelli , Thomas D. Kempe , Scott R. Presnell , Mohan Srinivasan , Susan C. Wong , Guodong Chen , Hui Wei , Stanley R. Krystek , Lumelle A. Schneeweis , Paul O. Sheppard , Indrani Chakraborty
IPC: A61K39/395 , C07K16/46 , C07K16/24 , A61K39/00
CPC classification number: C07K16/244 , A61K2039/505 , C07K16/468 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
Abstract translation: 本发明涉及使用包含与IL-17A和IL-17F交叉反应的结合实体的双特异性抗体和结合IL-23p19的结合实体来拮抗IL-17A，IL-17F和IL-23的活性 。 本发明涉及新的双特异性抗体形式及其使用方法。
-
公开(公告)号：US12129297B2
公开(公告)日：2024-10-29
申请号：US16961545
申请日：2019-01-11
Applicant: Bristol-Myers Squibb Company
Inventor： Xiao Min Schebye , Mark J. Selby , Michelle Minhua Han , Christine Bee , Andy X. Deng , Anan Chuntharapai , Brigitte Devaux , Huiming Li , Paul O. Sheppard , Alan J. Korman , Daniel F. Ardourel , Ekaterina Deyanova , Richard Yu-Cheng Huang , Guodong Chen , Michelle Kuhne , Hong-An Truong
CPC classification number: C07K16/2803 , A61P35/00 , G01N33/6854 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/74 , C07K2317/76 , C07K2317/92 , G01N2333/70503
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.
-
公开(公告)号：US20240228653A1
公开(公告)日：2024-07-11
申请号：US18543912
申请日：2023-12-18
Inventor： Robert J. Johnston , Andrew Rankin , Arathi Krishnakumar , Paul O. Sheppard , Arvind Rajpal
CPC classification number: C07K16/2896 , A61K45/06 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2319/30 , C07K2319/32
Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号：US20210017283A1
公开(公告)日：2021-01-21
申请号：US16982277
申请日：2019-03-19
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.06 seconds)
